Medications for Acute Coronary Syndromes
KEYWORDS: patients, orally, risk, heparin, pci, day, used, hours, bleeding, given, nitroglycerin, therapy, coronary, use, acs

Fibrinolytic Therapies Circulating half- Concurrent Allergic Medication life (minutes) heparin reactions Anistreplase 100 No Yes Alteplase 6 Yes Rare Reteplase 13–16 Yes Rare Streptokinase (not available in the 20 No Yes United States) Initial half-life of 20–24 minutes; Tenecteplase terminal phase Yes Rare half-life of 90–130 minutes CLINICAL CALCULATORS Intracranial Bleeding Risk from Thrombolytic Therapy of MI Contraindications to fibrinolytic therapy There are many absolute and relative contraindications to fibrinolytic therapy. In general, the presence of active bleeding or a condition where bleeding would be life-threatening is an absolute contraindication. The contraindications to fibrinolytic therapy are listed in the table Contraindications to Fibrinolytic Therapy. TABLE Contraindications to Fibrinolytic Therapy Absolute contraindications Aortic dissection Previous hemorrhagic stroke (at any time) Previous ischemic stroke within 1 year Active internal bleeding (not menses) 15/17 Intracranial tumor Pericarditis Blood pressure > 180/110 mm Hg after initial antihypertensive therapy Trauma or major surgery within 4 weeks Active peptic ulcer Relative contraindications Pregnancy Bleeding diathesis Noncompressible vascular puncture Current anticoagulation (INR > 2) Other Medications for Acute Coronary Syndromes Angiotensin-converting enzyme (ACE) inhibitors reduce mortality risk in patients with myocardial infarction, especially in those with anterior infarction, heart failure, or tachycardia. The greatest benefit occurs in
